🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

182 results for “Ars” Clear

  1. A study to investigate the pharmacokinetics of a combined oral contraceptive when given alone and in combination with GSK3036656 in female participants of non-childbearing potential aged 18 to 65 years of age

    GlaxoSmithKline

    Tuberculosis

    phase 1 other active

    1 trial

  2. A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

    GlaxoSmithKline

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  3. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  4. A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 years

    Bayer AG

    Heart failure in children

    phase 1 other active

    1 trial

  5. ARS-1 with URTI

    Ars Pharmaceuticals Irl Limited

    Upper Respiratory Tract Infection

    phase 1 small molecule completed

    1 trial

  6. An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  7. An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  8. Arsenic trioxide

    Teva Pharma GmbH

    Chronic Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial

  9. COVID-HIG

    United Therapeutics Europe Ltd

    SARS-CoV-2 Infection

    phase 1 mab completed

    1 trial

  10. Dociparstat sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  11. Drugs administration

    Hospital Authority, Hong Kong

    Rotator Cuff Tears of the Shoulder

    phase 1 small molecule active

    1 trial

  12. EDP-235

    ENANTA PHARMACEUTICALS INC

    SARS CoV 2 Infection

    phase 1 small molecule completed

    1 trial

  13. Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria

    Lacuna Pharma Pty Ltd

    Phenylketonuria

    phase 1 other active

    1 trial

  14. GB-0669

    Generate Biomedicines

    SARS CoV-2

    phase 1 small molecule completed

    1 trial

  15. IMM-BCP-01

    United Therapeutics Europe Ltd

    SARS-CoV2 Infection

    phase 1 small molecule terminated

    1 trial

  16. INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial

  17. Olezarsen

    IONIS PHARMACEUTICALS INC

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  18. Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  19. RE-021, sparsentan

    Travere Therapeutics

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  20. Recombinant SARS-CoV-2 Fusion Protein Vaccine

    Livzon Pharmaceutical Group

    COVID19

    phase 1 mab completed

    1 trial

  21. TNX-2110

    Tonix Pharmaceuticals Holding

    Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

    phase 1 mab terminated

    1 trial

  22. TP-03 (Lotilaner Ophthalmic Solution), 0.25%

    Tarsus Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  23. TP-05 (lotilaner oral capsules)

    Tarsus Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  24. TP-05 (lotilaner oral), fasted group

    Tarsus Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources